Fact-checked by Grok 2 weeks ago

Alchemax

Alchemax is a fictional megacorporation in , initially introduced in the Spider-Man 2099 series as the dominant corporate entity controlling vast sectors of a dystopian in the year 2099, specializing in , , , and advanced weaponry. Under leaders like Tyler Stone, it exemplified corporate overreach, employing figures such as Miguel O'Hara—whose genetic enhancement experiment granted him spider-like abilities—and engaging in practices like sabotaging competitors and manipulating public resources for profit. In later continuities, such as , Alchemax evolved into a multinational chemical and plastics conglomerate founded by industrialist Osborn, expanding into symbiote research and consumer products spanning food, transportation, and medicine, often clashing with through internal experiments and ethical lapses. The corporation's defining traits include its portrayal as a symbol of unchecked and technological , funding innovations like symbiote hosts and particle colliders while pursuing agendas that prioritize over societal welfare, as seen in conflicts with heroes across timelines. Notable controversies in its lore encompass drugging populations for control, illegal genetic tampering, and alliances with villains, underscoring themes of corporate villainy recurrent in Marvel's narratives.

Publication History

Creation and Debut in Comics

Alchemax was conceived by writer Peter David and artist Rick Leonardi as a central element of Marvel Comics' 2099 imprint, which envisioned futuristic iterations of classic characters in a cyberpunk dystopia dominated by corporate entities. The corporation debuted in Spider-Man 2099 #1, released on September 9, 1992, marking the launch of the series and the broader 2099 line. In this issue, Alchemax is established as a megacorporation controlling vast sectors of society in Nueva York of the year 2099, embodying themes of unchecked corporate power and genetic manipulation. The debut portrays Alchemax through the perspective of Miguel O'Hara, its director of the genetics division, who develops enhancements like the drug and corporate raiders—spies augmented with animal DNA for against competitors. This introduction sets Alchemax as both innovator and antagonist, funding O'Hara's spider-like genetic experiments that inadvertently lead to his transformation into after a attempt by a rival executive. The corporation's role underscores the 2099 universe's narrative of megacorps supplanting governments, with Alchemax's influence extending to public security via its Public Eye subsidiary. David's scripting emphasized Alchemax's ruthless efficiency, drawing from tropes while integrating 's superhero framework, as Leonardi's artwork depicted its towering headquarters and high-tech facilities to evoke a neon-lit, oppressive . The entity's immediate prominence in the debut issue propelled the series' exploration of and corporate overreach, with Alchemax's actions driving the inaugural storyline's conflict.

Evolution Across Marvel Imprints

Alchemax originated within the imprint, debuting in #1 (November 1992), written by with art by Rick Leonardi, as the dominant mega-corporation shaping the dystopia of Earth-928 in the year 2099. In this future timeline, Alchemax exerted near-total control over the , monopolizing sectors from and public utilities to and media, often through unethical experiments and corporate that directly antagonized protagonists like O'Hara, the genetically enhanced employed in its R&D division. The 2099 imprint, active from 1992 to 1998, positioned Alchemax as a symbol of unchecked in a possible extrapolation of the , influencing titles beyond , such as , where its subsidiaries facilitated resource extraction and genetic manipulation amid societal collapse. As the 2099 line waned, elements of its lore began crossing into the core continuity, prompting the introduction of an Alchemax counterpart in the present day. This iteration first manifested in The #19 (November 2013), amid Otto Octavius's tenure as the , where the corporation emerged as a cutting-edge firm tied to advanced tech initiatives, later headquartered in the repurposed Tower. In mainline publications, Alchemax shifted from futuristic hegemony to a multinational entity focused on chemicals, plastics, , and , led by figures like and involved in projects ranging from symbiote research to enhanced soldier programs, reflecting a retroactive bridging of 2099's corporate themes into contemporary narratives. Crossovers further evolved Alchemax's portrayal, with Miguel O'Hara's travels between and —such as in Spider-Man 2099 (vol. 2) #6 (2015)—exposing temporal links, including Tyler Stone's influence extending backward, allowing the corporation's 2099 excesses to inform 616 plots like Horizon Labs acquisitions and Venom-related experiments. This integration expanded Alchemax's scope across imprints, transforming it from an isolated future villainy into a versatile antagonist adaptable to multiversal events, without altering its core depiction as a profit-driven innovator prone to moral hazards.

Corporate Profile

Organizational Structure and Divisions

Alchemax maintains a divisional structure typical of megacorporations in the universe (Earth-928), with specialized units focused on innovation, environmental management, and internal security, overseen by high-ranking executives. The Research and Development (R&D) division drives core technological and biological advancements, including programs aimed at enhancing human capabilities through animal DNA splicing and other alterations. Within R&D, the genetics program represents a key sub-unit, where scientists like Miguel O'Hara led projects to replicate traits, often prioritizing corporate profit over ethical constraints. Eco Central operates as the environmental division, tasked with pollution mitigation and public image management, though it has been exposed as a front concealing Alchemax's broader ecological harms, such as dumping. Paul-Phillip Ravage directed this division prior to defecting upon discovering its duplicitous role. Subsidiary entities extend Alchemax's influence into governance-like functions; the Public Eye serves as a privatized security and enforcement arm, functioning as in Alchemax-controlled territories. In iterations, Alchemax Genetics emerges as a prominent under leaders like Dr. Robert Chandler, emphasizing similar biotechnological pursuits amid mergers with entities such as . Overall leadership in the 2099 timeline centers on figures like Tyler Stone, who directed R&D as , reflecting the corporation's hierarchical command where heads report to an cadre prioritizing expansion and control.

Leadership and Key Personnel

Tyler Stone headed Alchemax's Research and Development division in the Earth-928 timeline, directing genetic experiments that combined human and animal DNA to replicate superhuman abilities, including those that empowered O'Hara as 2099. As a high-ranking executive and owner of the corporation, Stone wielded significant influence over its operations in the corporate-dominated society of 2099. In the continuity, Liz Allan Osborn serves as President and CEO, having built the company by merging her father's Allan Chemical with remnants after Harry Osborn's death, positioning Alchemax as a major player in biotechnology and advanced weaponry. She oversees family-linked initiatives, such as supporting her brother Mark Raxton's rehabilitation as . Tiberius Stone, son of Tyler Stone, acts as a key executive under Allan, managing projects like the Spider-Slayer and supervising transferred personnel from facilities such as Horizon Labs. Mason Banks, the Chief of Staff, assists in daily operations but was later exposed as following reconstructive surgery, advancing schemes to secure a legacy through his grandson . Other notable leadership figures include Dr. Robert Chandler and Captain Mooney, who directed Alchemax's genetics division and oversaw controversial cloning experiments involving subjects like X-23. In Earth-928, personnel such as Paul-Phillip Ravage led subsidiary Eco Central, focusing on environmental technologies amid corporate expansion.

Fictional Timeline

Origins and Rise in Earth-928

Alchemax established itself as the preeminent megacorporation in Earth-928 by 2099, controlling vast sectors of the economy, particularly in Nueva York, through diversified operations in research, security, and urban services. The corporation's dominance reflected the broader shift in the timeline toward replacing traditional state authority, with Alchemax leveraging advanced R&D to secure market superiority over rivals like Stark-Fujikawa and Venture. Its headquarters in a towering symbolized this ascent, enabling oversight of daily life via integrated subsidiaries. Central to Alchemax's rise was the leadership of Tyler Stone, its owner and CEO, who directed aggressive expansion into and starting from at least the late . Stone prioritized proprietary innovations, such as projects aimed at replicating abilities for corporate advantage, exemplified by the genetics division under Miguel O'Hara. These initiatives, while driving technological breakthroughs, often involved high-risk experimentation that blurred ethical boundaries, contributing to Alchemax's reputation for ruthless efficiency. Alchemax solidified its power through control of essential services, including the Public Eye security force, which operated as a privatized entity enforcing corporate interests across Nueva York. This infrastructure, combined with ventures into environmental and infrastructural projects, allowed the corporation to monopolize resources amid the timeline's economic upheavals. However, such expansion drew scrutiny for practices like covert pollution, as evidenced by internal discoveries linking Alchemax to framed against whistleblowers. By 2099, these elements had elevated Alchemax to near-sovereign status, intertwining its fate with key figures like O'Hara, whose enhancements stemmed directly from its labs.

Adaptation and Events in Earth-616

Alchemax entered continuity in The Superior Spider-Man #19 (February 2014), formed through the merger of Allan Chemical—owned by Elizabeth "Liz" Allan Osborn—with assets inherited by her son and financial contributions from the Stone family, including Tiberius Stone. This adaptation reimagined the corporation as a present-day multinational entity focused on chemicals, , and advanced materials, distinct from its dystopian dominance in Earth-928, while incorporating ancestral ties to facilitate cross-timeline influences from 2099. The merger positioned Alchemax as a rival to legacy firms like , emphasizing rapid expansion into and corporate intrigue amid -related conflicts. Miguel O'Hara, the of Earth-928, infiltrated Alchemax's early operations by posing as an employee named to monitor and subtly redirect Tiberius Stone—his grandfather in the 2099 lineage—away from unethical paths that could precipitate corporate overreach. This intervention aimed to avert the authoritarian future Alchemax fostered in 2099, marking a causal link between timelines where O'Hara's actions sought to preserve ethical boundaries in Earth-616's version of the company. Under subsequent leadership, particularly as CEO following her husband's death and inheritance maneuvers, Alchemax consolidated power, leveraging Oscorp's remnants to pursue aggressive R&D in symbiote-related projects and . In later events, Alchemax engaged in symbiote experimentation, analyzing offshoots of the Carnage symbiote and exposing samples to compounds to explore bonding limits and weaponization potential, contributing to broader conflicts like the Venom War in 2024. These initiatives culminated in the creation or facilitation of the Misery symbiote, which bonded with and her associate during an assault on Alchemax facilities, amplifying the company's role in escalating symbiote-host dynamics and drawing heroic intervention. Such activities underscored Alchemax's pattern of prioritizing proprietary advancements over regulatory oversight, echoing but diverging from its 2099 counterpart through integration into mainline narratives involving multiversal threats and corporate espionage.

Alternate Realities and Crossovers

In the primary continuity of , Alchemax dominates as a mega-corporation controlling vast sectors of society in Nueva York circa 2099, but its influence extends to other realities through temporal and multiversal crossovers involving (Miguel O'Hara). A distinct iteration of Alchemax operates in , Marvel's core universe, functioning as a multinational chemical and biotech firm headquartered in under the leadership of Tiberius "Ty" Stone, a scientist and CEO with ties to early competitors. This version emerged as part of efforts to retroactively link the 2099 timeline to present-day events, with Stone positioned as the grandfather of Tyler Stone, Alchemax's Earth-928 executive. Miguel O'Hara, traveling back from 2099, assumes the alias Michael "Mike" O'Mara to safeguard Stone and facilitate Alchemax's foundational development in the , blending corporate intrigue with time-travel to avert disruptions to his own origin. Crossovers amplify Alchemax's reach during incursions, where O'Hara's interventions in intersect with threats like the Inheritors, indirectly exposing Alchemax's legacy—such as Rapture-derived enhancements—to heroes like Peter Parker. In the 1994 Fall of the Hammer event within the 2099 line, Alchemax orchestrates alliances with Norse-inspired entities like the Aesir to consolidate power, though confined to Earth-928 dynamics. These narratives underscore Alchemax's recurring motif as a catalyst for ethical breaches in genetic manipulation across timelines, with iterations experimenting in symbiotes and advanced prosthetics that echo 2099 excesses. No verified depictions place Alchemax in unrelated realities like Earth-1610 or Earth-2149, limiting its multiversal footprint to 2099-616 convergences.

Innovations and Projects

Genetic and Biotechnology Initiatives

Alchemax's genetics division in Earth-928 spearheaded efforts to engineer superhuman enhancements for corporate and military advantage, with Miguel O'Hara serving as director of the program aimed at producing soldiers possessing controlled superpowers through DNA manipulation. The initiative focused on splicing human genetic material with animal traits to yield operatives capable of superior strength, agility, and other attributes, positioning Alchemax to dominate competitive sectors via biologically augmented personnel. A pivotal experiment involved O'Hara's self-application of a genetic resequencer incorporating spider DNA on February 13, 2099, intended to forge a for "corporate raiders" with predatory efficiencies; by Alchemax executive Tyler Stone, who laced the mixture with a corporate drug, rendered the alteration permanent, granting O'Hara arachnid abilities including enhanced strength, web-like projection from talons, and accelerated healing. This incident, stemming from Alchemax's pressure for expedited results in , underscored the corporation's prioritization of rapid innovation over safety protocols. In , Alchemax Genetics, a specialized biotech arm, advanced cloning technologies by deriving ten clones from the genetic template of , under the supervision of a dedicated research team, expanding the firm's portfolio into regenerative and replicative biology for potential defense and medical uses. These projects integrated with Alchemax's broader pharmaceutical operations, which supplied biotech-derived products for health and enhancement markets, though ethical lapses in human experimentation drew scrutiny from external actors.

Advanced Technology Developments

Alchemax's division in Earth-928 focused on cybernetic enhancements and robotic systems to bolster corporate security and enforcement capabilities. These included augmentations for operatives like Venture, a cyborg mercenary equipped with reinforced exoskeletal armor granting superhuman strength, durability, and weaponized appendages for urban combat and facility defense. Such technologies were integral to the Public Eye force, Alchemax's privatized police entity, which deployed automated drones and networked surveillance arrays for real-time threat assessment across Nueva York. A landmark achievement was the Chronosphere, a sophisticated temporal monitoring apparatus engineered to track and stabilize fluctuations for strategic advantage. Approved by CEO Tyler Stone, the device inadvertently generated timestorms by interfacing with historical events, pulling figures from earlier eras into 2099 and destabilizing reality until corrected. This innovation underscored Alchemax's pursuit of and causality manipulation, though it exposed vulnerabilities to external interference from AI systems like Lyla. In , Alchemax adapted similar principles to , with R&D heads developing upgraded Spider-Slayer units—autonomous hunter-killer machines optimized for targeting enhanced individuals through adaptive algorithms and energy weaponry. These constructs, deployed against and temporal variants, demonstrated iterative advancements in AI-driven targeting and modular armor. The further incorporated salvaged artifacts from prior heroic eras, reverse-engineering energy shields and propulsion systems to enhance orbital platforms and defensive perimeters.

Conflicts and Ethical Issues

Antagonistic Encounters with Heroes

Alchemax's primary antagonistic encounters have centered on (Miguel O'Hara), a former high-ranking employee in its division. O'Hara's transformation into the hero occurred after Tyler Stone, an Alchemax executive, sabotaged his experimental project by dosing him with a genetic cocktail incorporating spider DNA, granting enhanced abilities amid the corporation's pursuit of superhuman enhancements. This betrayal fueled O'Hara's vigilantism against Alchemax's monopolistic control over Nueva York, including its exploitation of citizens through addictive substances and unethical . Key clashes involved O'Hara battling Alchemax's private security force, the Public Eye, which enforced corporate interests with militarized precision. Stone, later revealed as O'Hara's biological father through coerced relations with O'Hara's mother, escalated personal stakes by ordering attacks on O'Hara's associates and facilities, such as the destruction of his apartment complex to eliminate evidence of internal dissent. Alchemax-backed operatives, including enhanced enforcers like Venture (John Braddock), directly confronted in efforts to suppress threats to proprietary technologies and market dominance. In broader integrations, Alchemax has opposed (Peter Parker), positioning the corporation as a threat through ventures into symbiote manipulation and collider experiments that endangered public safety and drew heroic intervention. Leadership under figures like Liz Allan-Osborn amplified these tensions, with Alchemax's internal corruption prompting alliances against it, such as symbiote hosts targeting its facilities to expose illicit projects. 2099's incursions into present-day timelines further pitted him against Alchemax remnants, reinforcing the entity's role as a recurring adversary to web-slinging protectors.

Criticisms of Corporate Practices

Alchemax's genetic research division, under the direction of figures like Miguel O'Hara, engaged in human experimentation that drew internal ethical concerns, including tests on prisoners as subjects for unproven biotechnologies. O'Hara, troubled by the lethal risks to participants, sought to resign in 2099, prompting CEO Tyler Stone to lace his farewell drink with , a potent , effectively addicting him to retain his expertise and silence his objections. This incident exemplified broader accusations of coercive retention tactics and disregard for employee autonomy within the corporation's high-stakes R&D environment. The company's dominance in Nueva York extended to monopolistic control over public services, including the privatization of security via the Public Eye force, which critics portrayed as an extension of Alchemax's profit-driven agenda over civic welfare. In Earth-928's timeline, Alchemax's promotion of as a productivity enhancer led to widespread across the populace, with the corporation allegedly engineering dependency to bolster workforce compliance and consumer markets. Such practices fueled narratives of systemic , where corporate prioritized over human costs, as evidenced by genetic incidents that inadvertently or deliberately altered employees' DNA for proprietary gains. In alternate depictions, such as integrations, Alchemax faced scrutiny for releasing untested compounds into public water supplies to gauge real-world reactions, resulting in unintended and crises among civilians. These actions, often justified internally as accelerating , underscored persistent critiques of the corporation's causal prioritization of experimental speed over safety protocols and .

Depictions in Adaptations

Television and Animation

Alchemax has been portrayed in Marvel's animated television series primarily as a corporation engaged in cutting-edge research with ethically questionable practices. Its Earth-928 incarnation, representing the dystopian future megacorporation from the Marvel 2099 imprint, debuted in the Ultimate Spider-Man episode "The Spider-Verse: Part 1," the ninth episode of season 3, which originally aired on February 27, 2015. In this storyline, Peter Parker travels to the year 2099 and encounters Miguel O'Hara, Spider-Man 2099, whose genetic enhancements originated from Alchemax experiments; the company is depicted as a dominant entity in Nueva York's corporate landscape, with visual cues like advertisements highlighting its pervasive influence. The version of Alchemax appeared in the Marvel's Spider-Man animated series, season 2, episode 18 titled "," which premiered on October 6, 2019. Here, Alchemax operates as a contemporary firm under CEO Tiberius Stone, who conducted illicit experiments on teenagers Tyrone Johnson and Tandy Bowen, granting them superhuman powers as ; the duo seeks vengeance against the company for the resulting hardships, portraying Alchemax as a beneficiary of Midtown High that prioritizes profit over safety. Stone's cold demeanor and the firm's role in power-granting incidents underscore themes of corporate irresponsibility, aligning with comic depictions but adapted for a younger audience with Superior Spider-Man intervening to contain the conflict. These animated appearances emphasize Alchemax's recurring motif as an antagonist enabler of origins through genetic and technological meddling, though scaled for episodic formats without delving into the full scope of its subsidiaries or city-wide control. No dedicated has centered on Alchemax to date, with its roles limited to supporting elements in or origin-focused narratives.

Video Games and Interactive Media

Alchemax serves as a key antagonistic entity in the 2011 action-adventure video game Spider-Man: Edge of Time, developed by and published by for multiple platforms including , , and . In the game's narrative, set partially in the year 2099, Alchemax is portrayed as a megacorporation exerting near-total control over society, creating a dystopian environment devoid of freedoms. Alchemax scientist Walker Sloan engineers the Chrono-Legion, an artificial intelligence-based army, to facilitate back to the present day, aiming to amass power by leveraging future knowledge and accelerating the company's dominance. A pivotal reveals Peter Parker as the future CEO of Alchemax, having utilized the firm's anti-aging to extend his life, though he ultimately aids in averting Sloan's timeline alterations. The corporation receives a more peripheral depiction in Marvel's (2018), an open-world action game developed by for PlayStation 4. Here, Alchemax functions as a chemical manufacturing firm with facilities in , serving as the location for the side mission "Tombstone: What's He Building in There," where infiltrates the plant to disrupt Tombstone's production of the performance-enhancing drug Diox-3. The mission involves stealth segments amid chemical vats and robotic security, highlighting Alchemax's industrial operations within the game's Earth-1048 universe. Alchemax makes brief appearances in other titles, such as the 2010 game Spider-Man: Shattered Dimensions, where its branding is visible during sequences set in the 2099 reality, underscoring its corporate influence in Miguel O'Hara's era. These portrayals consistently emphasize Alchemax's role in advancing unethical technologies and corporate overreach, aligning with its origins while adapting to interactive gameplay mechanics like time manipulation and facility infiltrations.

References

  1. [1]
    Alchemax Members, Enemies, Powers | Marvel
    Led by industrialist Liz Allan, Alchemax is a mega-corporation that creates plastic, chemical, and agricultural products. They touch every major part of ...
  2. [2]
    Meet Liz Allan, Marvel's Latest Symbiote Host
    May 3, 2023 · Meet the Alchemax CEO, who built a megacorporation out of her late husband's business and recently bonded with a symbiote known as Misery.Liz Allan's Marvel Origins · Liz Allan's Tragic Love Life · Liz Allan: A True Marvel...
  3. [3]
    Get to Know Spider-Man 2099 - Marvel.com
    Nov 5, 2019 · Spider-Man 2099 (1992) #1​​ He'd been tasked with designing Corporate Raiders, Alchemax-owned spies who would utilize animal-based genetic ...
  4. [4]
    Go Back to the Future with 'Spider-Man 2099' #1 - Marvel.com
    Dec 19, 2019 · ... Peter Parker's clone… spider-man 2099. Read Spider-Man 2099 #1 today by Peter David and Rick Leonardi for the full origin, and continue the ...
  5. [5]
    Character: Alchemax; powerful corporation in 2099
    Name: Alchemax. Classification: villains group. Publisher(s): Marvel. First Appearance: Spider-Man 2099 (vol. 1) #1 (Nov. 1992): "Spider-Man 2099".
  6. [6]
    Ravage 2099: What Ever Happened To Marvel's Forgotten Future ...
    Dec 28, 2020 · Marvel's 2099 imprint, which lasted from 1992 to 1998, took readers to the far-flung future of the publisher's shared universe.
  7. [7]
    Spider-Man 2099 (Vol. 2) #6 - SpiderFan.org
    On Earth-928 of the year 2099, following the events of Superior Spider-Man #19, Tyler Stone sits relaxed at his desk in the Alchemax Tower. Stone happily ...<|separator|>
  8. [8]
    Spider-Man 2099 (Miguel O'Hara) Powers, Enemies, & History | Marvel
    ### Summary of Alchemax Divisions Miguel O'Hara Worked In
  9. [9]
    Ravage (Earth-928) Powers, Enemies, History - Marvel
    Paul-Phillip Ravage was the head of Eco Central, a division of Alchemax, in the year 2099, until he grew curious and investigated the claims of a young man ...
  10. [10]
    Spider-Man 2099 - Character Profiles - Doom2099.com
    Spider-Man 2099 #46: Bombs Alchemax. 2099 ... Following Doom's take over of America, Miguel assumed Tyler Stone's position as VP of Alchemax's R&D division.
  11. [11]
    Punisher (Earth-928) Powers, Enemies, History - Marvel.com
    The Punisher soon discovered a link between the Cyber Nostra and Alchemax when he found the criminal group cleaning up Alchemax's genetic experiments. He ...
  12. [12]
    Tyler Stone (Character) - Comic Vine
    Tyler Stone is the owner of the Alchemax corporation. It is eventually revealed that he is Spider-Man 2099's father. Creation. Tyler Stone was created by Peter ...Missing: structure | Show results with:structure
  13. [13]
    Who Is ACROSS THE SPIDER-VERSE'S Spider-Man 2099? - Nerdist
    Jun 9, 2023 · However, it was later revealed as Earth-928. Miguel was the head of the genetics department at the mega-corporation called Alchemax. He spent ...
  14. [14]
    Superior Spider-Man #19 [in Comics & Books] @ SpiderFan.org
    The 'Oscorp' name is coming off of her skyscraper, to be replaced by 'Alchemax', which has been formed by a merger of Allan Chemical, Oscorp, and the ...
  15. [15]
    Superior Spider-Man #19 - Nick Peron
    Nov 11, 2020 · This man is actually Miguel O'Hara, the Spider-Man of 2099, who has decided to keep close tabs on his grandfather and Alchemax and steer them ...
  16. [16]
    Every Marvel Symbiote, from Venom to Knull
    Jun 1, 2023 · That story revealed Alchemax has been studying various offshoots of the Carnage symbiote and exposing it to Anti-Venom.
  17. [17]
    Meet Miguel O'Hara, Spider-Man 2099 - Marvel.com
    May 26, 2023 · ... Tyler Stone. O'Hara's job at Alchemax centered on mixing the genetic code of animals with that of humans to create people with abilities ...<|separator|>
  18. [18]
    The Top 10 Time-Travelers in the Marvel Universe
    Jun 27, 2023 · Taking on the identity of Michael “Mike” O'Mara, Miguel began working for Alchemax, the company that were a critical part in his life circa 2099 ...
  19. [19]
    THE FALL OF THE HAMMER (1994) - The Marvel Comics Guide
    Mar 22, 2021 · THE RISE OF THE HAMMER - Alchemax recruits the Aesir and raise Valhalla. Crossover: A standard five-part crossover with an optional epilogue ...
  20. [20]
    Who is Spider-Man 2099 - The Futuristic Sci-Fi Arachnid Version
    Apr 27, 2023 · Miguel O'Hara is a scientist who becomes head of the Alchemax genetics program. The aim was to generate new soldiers with controlled superpowers.
  21. [21]
    Spider-Man 2099 (Vol. 1) #2 - SpiderFan.org
    In the year 2099, Miguel O'Hara, brilliant scientist and head of the Genetics Program at Alchemax Corporation, attempted to reset his genetic code after his ...
  22. [22]
    Venture (Earth-928)
    Dec 7, 2017 · Identity/Class: Extradimensional (Earth-928) human cyborg (circa 2099 A.D.). Occupation: Mercenary. Group Membership: The Alchemax Elite Corps ( ...
  23. [23]
    SPIDER-MAN 2099 (Exiles) | uncannyxmen.net
    May 14, 2015 · Tyler Stone reclaimed the position of Alchemax CEO from Miguel, and O'Hara continued having secret adventures as Spider-Man 2099. The exact ...
  24. [24]
    Spider-Man 2099 (Miguel O'Hara)
    Dec 5, 2003 · (Spider-Man 2099#1 (fb)) - At Alchemax, Miguel O'Hara headed the genetics program, where he was pressured by his boss, Tyler Stone, to work on ...<|separator|>
  25. [25]
    W.E.B. Explainer: Every Marvel Character Named in Spider-Man ...
    Feb 19, 2025 · As head of Alchemax's R&D Department, he designed next-gen Spider-Slayers that battled both Spider-Man and Spider-Man 2099 in the present day MU ...Videos By Comicbook.Com · Max Dillon · Ned Leeds
  26. [26]
    A Retrospective: Spider-Man 2099 - by deidre - mirroring life
    Jul 20, 2023 · In the beginning of Spider-Man 2099, aka Miguel O'Hara's origins, we see that the all-powerful Alchemax is using prisoners as test subjects for ...Missing: practices criticisms
  27. [27]
    Looking back at the original Spider-Man 2099 run with Peter David
    Jul 13, 2005 · Joined by artist Rick Leonardi for roughly half of its 46-issue run, the series started off with a buzz as one of the hippest and smartest books in the line.<|control11|><|separator|>
  28. [28]
    SPIDER-MAN 2099 (Exiles) | uncannyxmen.net
    May 14, 2015 · The animal testing phase seemed promising, and Miguel began working on genetic templates for future human trials, including a spider template ...
  29. [29]
    7 Marvel Companies More Evil Than Their Villains - ComicBook.com
    Sep 6, 2025 · In the year 2099, the city of Nueva York is ruled by the corrupt chemical corporation known as Alchemax. Everything in Nueva York is tied to and ...
  30. [30]
    HERO HISTORY: Spider-Man 2099 - MAJOR SPOILERS
    Jul 4, 2013 · Though highly respected at Alchemax, Miguel is not universally loved, but he DOES have more of a conscience than many of his compatriots. When a ...<|separator|>
  31. [31]
    Spider-Man: How Peter Parker's Friend Liz Allan Shaped Marvel's ...
    Feb 13, 2021 · In one of Marvel's most famous future timelines, Spider-Man 2099 is a byproduct of his former employer's tampering with genetic experimentation.
  32. [32]
    Spider-Man Attended the X-Men's School As A Child - Screen Rant
    Oct 14, 2020 · When he was forced to perform unethical and lethal genetic experiments on humans, however, Miguel tried to quit Alchemax and was tricked ...<|separator|>
  33. [33]
    Ultimate Spider-Man: Web Warriors "The Spider-Verse, Part One"
    After discovering Alchemax, the first alternate hero Spidey meets is Spider-Man 2099. Before I continue, I must say Spider-Man 2099 is easily my favorite ...
  34. [34]
    "Spider-Man" Cloak and Dagger (TV Episode 2019) - IMDb
    Rating 7/10 (124) When Cloak and Dagger emerge to take revenge against Tiberius Stone and his company, Alchemax, Superior Spider-Man must take them down to protect the school.
  35. [35]
    Cloak and Dagger - Marvel's Spider-Man (Season 2, Episode 18)
    Oct 6, 2019 · When Cloak and Dagger emerge to take revenge against Tiberius Stone and his company, Alchemax, Superior Spider-Man must take them down to ...Missing: animated | Show results with:animated
  36. [36]
    Cloak and Dagger | Marvel's Spider-Man S2 E18 | Full Episode
    Aug 31, 2024 · When Cloak and Dagger emerge to take revenge against Tiberius Stone and his company, Alchemax, Superior Spider-Man must take them down to ...
  37. [37]
    Spider-Man: Edge of Time - Wikipedia
    Spider-Man: Edge of Time is a 2011 action-adventure video game based on the Marvel Comics superhero Spider-Man, developed by Beenox and published by Activision
  38. [38]
    https://dcanimated.com/WF/sections/specials/spidermantas/interviews/other/edgeoftime/
  39. [39]
    Spider-Man: Edge of Time - The World's Finest
    As the story goes, Alchemax scientist Walker Sloan - in the year 2099 - seeks to gain power and fortune by traveling back in time to the present day and use his ...<|control11|><|separator|>
  40. [40]
    Spider-Man: Edge of Time (Video Game) - TV Tropes
    The plot kicks off when Alchemax scientist Walker Sloan travels back to modern-day New York and uses his future tech to found Alchemax decades ahead of when it ...
  41. [41]
    Tombstone: What's He Building in There - Marvel's Spider-Man Guide
    Sep 7, 2018 · This page contains information on one of the Side Missions - Tombstone: What's He Building in There - which will include main objectives, side objectives, and ...
  42. [42]
    Alchemax - Multiversal Omnipedia
    Oct 11, 2023 · Alchemax is a powerful, global mega-corporation in Marvel Comics, created by Liz Allan, and was a global corporation operating on Earth.